JP5514099B2 - プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用 - Google Patents

プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用 Download PDF

Info

Publication number
JP5514099B2
JP5514099B2 JP2010501589A JP2010501589A JP5514099B2 JP 5514099 B2 JP5514099 B2 JP 5514099B2 JP 2010501589 A JP2010501589 A JP 2010501589A JP 2010501589 A JP2010501589 A JP 2010501589A JP 5514099 B2 JP5514099 B2 JP 5514099B2
Authority
JP
Japan
Prior art keywords
isopropyl
purin
ylamino
cancer
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010501589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523536A (ja
JP2010523536A5 (enExample
Inventor
サイモン グリーン
シーラー フレイム
イアン フレミング
Original Assignee
サイクラセル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイクラセル リミテッド filed Critical サイクラセル リミテッド
Publication of JP2010523536A publication Critical patent/JP2010523536A/ja
Publication of JP2010523536A5 publication Critical patent/JP2010523536A5/ja
Application granted granted Critical
Publication of JP5514099B2 publication Critical patent/JP5514099B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010501589A 2007-04-04 2008-04-02 プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用 Expired - Fee Related JP5514099B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92169907P 2007-04-04 2007-04-04
GBGB0706633.5A GB0706633D0 (en) 2007-04-04 2007-04-04 Combination
GB0706633.5 2007-04-04
US60/921,699 2007-04-04
PCT/GB2008/001189 WO2008122779A1 (en) 2007-04-04 2008-04-02 Combination of a purine-based cdk inhibitor with a tyrosine kinase inhibitor and use thereof in the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2010523536A JP2010523536A (ja) 2010-07-15
JP2010523536A5 JP2010523536A5 (enExample) 2011-04-21
JP5514099B2 true JP5514099B2 (ja) 2014-06-04

Family

ID=38090894

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501589A Expired - Fee Related JP5514099B2 (ja) 2007-04-04 2008-04-02 プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用

Country Status (6)

Country Link
US (1) US9173938B2 (enExample)
EP (1) EP2139486A1 (enExample)
JP (1) JP5514099B2 (enExample)
CN (1) CN101678029B (enExample)
GB (1) GB0706633D0 (enExample)
WO (1) WO2008122779A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
KR20110010787A (ko) 2008-06-17 2011-02-07 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
CN113209121A (zh) 2008-08-04 2021-08-06 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
WO2010104923A1 (en) * 2009-03-11 2010-09-16 Research Development Foundation Low molecular weight cyclin e (lmw-e) as a biomarker for personalization of cancer therapies
IL264349B2 (en) 2009-04-06 2024-01-01 Wyeth Llc Regimen comprising neratinib for the treatment of cancer
FR2945747A1 (fr) * 2009-05-25 2010-11-26 Centre Nat Rech Scient Composition pharmaceutique antitumorale comprenant un inhibiteur de cdks et un inhibiteur de la croissance cellulaire
AU2010319483B2 (en) * 2009-11-13 2015-03-12 Amgen Inc. Material and methods for treating or preventing HER-3 associated diseases
PT2509599E (pt) * 2009-12-11 2014-10-15 Niiki Pharma Inc Processo para o tratamento de cancro pancreático
GB201001075D0 (en) * 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
CN103313713B (zh) 2010-08-26 2014-12-31 和谐进化股份有限公司 受体型激酶调节剂和多囊性肾病的治疗方法
TW201300105A (zh) 2011-05-31 2013-01-01 Piramal Life Sciences Ltd 治療頭頸鱗狀細胞癌之相乘藥物組合物
EP2874631A1 (en) 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
US11007174B2 (en) 2013-07-12 2021-05-18 Piramal Enterprises Limited Pharmaceutical combination for the treatment of melanoma
MX2017013383A (es) 2015-04-20 2017-12-07 Tolero Pharmaceuticals Inc Prediccion de respuesta a alvocidib mediante perfilado mitocondrial.
ES2739749T3 (es) 2015-05-18 2020-02-03 Tolero Pharmaceuticals Inc Profármacos de alvocidib que tienen biodisponibilidad aumentada
EP3331510A4 (en) * 2015-08-03 2019-04-03 Tolero Pharmaceuticals, Inc. COMBINATION THERAPIES FOR THE TREATMENT OF CANCER
CN108135900A (zh) 2015-09-04 2018-06-08 亚狮康私人有限公司 包含瓦尼替尼及抗癌剂之组合疗法
WO2017160568A1 (en) 2016-03-16 2017-09-21 Eli Lilly And Company Combination therapy comprising the cdk4/6 inhibitor necitumumab and the egfr inhibitor abemaciclib for use in treating cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
CN115737636B (zh) * 2017-01-10 2024-08-27 浙江嘉驰医药开发有限公司 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
EP4036583A1 (en) * 2017-08-11 2022-08-03 Board of Regents, The University of Texas System Targeting kinases for the treatment of cancer metastasis
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
CN111867586A (zh) * 2018-03-13 2020-10-30 得克萨斯州大学系统董事会 用于治疗具有egfr激活突变的癌症的方法
JP2021525244A (ja) * 2018-05-23 2021-09-24 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． 腫瘍性疾患を治療するための薬剤の調製におけるｅｇｆｒ阻害剤と組み合わせたｃｄｋ４／６阻害剤の使用
CA3119807A1 (en) 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
GB202000901D0 (en) * 2020-01-22 2020-03-04 Cyclacel Ltd Process
CN116813621A (zh) * 2023-06-08 2023-09-29 江南大学 9h嘌呤类化合物及其药物组合物和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
EP1558289A1 (en) 2002-11-06 2005-08-03 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
GB0523040D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
EA200802058A1 (ru) * 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции

Also Published As

Publication number Publication date
GB0706633D0 (en) 2007-05-16
US20100143350A1 (en) 2010-06-10
EP2139486A1 (en) 2010-01-06
CN101678029A (zh) 2010-03-24
US9173938B2 (en) 2015-11-03
CN101678029B (zh) 2012-07-18
JP2010523536A (ja) 2010-07-15
WO2008122779A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
JP5514099B2 (ja) プリンに基づくｃｄｋ阻害剤とチロシンキナーゼ阻害剤の組合せ、及び増殖性障害の治療におけるその使用
ES2535404T5 (es) Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama
TW202317100A (zh) 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
US20230330243A1 (en) Combination of antibody-drug conjugate and atr inhibitor
RU2496500C2 (ru) Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr
KR20200078495A (ko) 암 치료를 위한 조성물 및 방법
JP7123806B2 (ja) 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ
CN111527103A (zh) 用于治疗或预防her驱动的抗药性癌症的化合物、组合物和方法
JP2021536507A (ja) Ｈｅｒ駆動性がんを治療または予防するための化合物、組成物、及び方法
JP2018511643A (ja) 癌を治療するための方法
Ling et al. Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
JP2008501708A (ja) がんの治療方法
US20100226919A1 (en) Antitumoral Treatments
US20130150386A1 (en) Methods for the treatment of lung cancer
AU2005251722B2 (en) Cancer treatment method
US20190125751A1 (en) Anticancer combination therapy
KR102528732B1 (ko) 포지오티닙 및 칼슘채널 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4534085A1 (en) Compounds for use in methods of treating cancer
US20120035183A1 (en) Cancer Treatment Method

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130212

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130507

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140106

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140114

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140328

R150 Certificate of patent or registration of utility model

Ref document number: 5514099

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees